Mon, June 19, 2017

Led by Chad A. Mirkin, George B. Rathmann Professor of Chemistry in the Weinberg College of Arts and Sciences and director of the IIN, the Willens Center supports interdisciplinary research focused on developing and applying advances in nanotechnology to treat the most aggressive types of cancer.

“The potential for using nanotechnology in the fight against cancer is vast,” Mirkin said. “The generous support from the Willens family is enabling researchers to work toward the development of new medicines that can attack the disease at its genetic roots. Certain types of nanostructures, spherical nucleic acids in particular, can deliver therapeutics into tissues many drugs normally will not enter, including the brain and skin.”

Ron Willens said he and his wife were humbled by the University’s achievements in research. “Ten or 15 years ago, who would have imagined that a tiny submicroscopic particle could be used to transport the means to potentially treat and cure many cancers? With this gift, we are grateful that we are able to contribute to this endeavor where minds can do research, innovate and stretch their imagination to find new frontiers to help humanity,” he said.

Fri, April 28, 2017

Strategically complementary combination to enhance and diversify Fresenius Kabi’s business and portfolio.  "Joining our two companies and product portfolios will strengthen and diversify both businesses,” said John Ducker, president and CEO of Fresenius Kabi USA. “Akorn brings to Fresenius Kabi specialized expertise in development, manufacturing and marketing of alternate dosage forms, as well as access to new customer segments like retail, ophthalmology and veterinary practices. Its pipeline is also impressive, with approximately 85 ANDAs filed and pending with the FDA and dozens more in development.”

“Fresenius Kabi is an excellent fit for Akorn, strategically and culturally,” said Raj Rai, Akorn’s Chief Executive Officer. “Fresenius brings to Akorn the strength and resources of a global leader with an experienced U.S. team and an outstanding record of growth and award-winning service in the United States. We look forward to working with Fresenius Kabi on this next phase of our growth. When the transaction closes, we will strive to ensure a smooth transition for our employees and customers.”


April 2017

Fresenius Kabi to Acquire Akorn

Strategically complementary combination to enhance and diversify Fresenius Kabi’s business and portfolio.  "Joining our two... Read on >

Governor Rauner Visits ISTP

“The Illinois Science and Technology Park is on the forefront of innovation to help grow Illinois.  This facility allows for smaller... Read on >

March 2017

Skokie 2016 Update

The Village of Skokie enjoyed another high profile year, particularly in terms of total retail sales growth, ranking #1 among the Top 20... Read on >

American Landmark Properties announced ISTP acquisition

“The Illinois Science + Technology Park represented a rare opportunity to acquire one of Chicago’s premier life science and technology campuses,”... Read on >